← boardnext 2030-02next 2030-07
VCEL
Vericel Corporationdistress 0/10 · well-funded / low risk$44.410%today-8% from 52w high
Lead: Chondral Defect
Revenue
$68M
Liquidity
$145M
Runway
—
Shares 1y
+1%
Price & events
+13.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-7.1%
1W
+10.0%
1M
+29.1%
3M
+17.3%
6M
+10.1%
1Y
-16.0%
2Y
-16.6%
5Y
+43.6%
All
Overview
- Market Cap
- $2.27B
- Volume
- 23.00K
- 52 Week Range
- $29.34 – $48.31
- Total Shares
- 51.07M
- Float Shares
- 50.44M
- Short %
- 12.40%
- % Held by Insiders
- 1.19%
- % Held by Institutions
- 113.68%
- RVOL
- 0.04x
- Beta
- 1.07
Pipeline stages · 2 programs
MACI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
autologous cultured chondrocytes on porcine collagen membrane
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2030-02 Estimated 50% readout ~2030-04-17 | Phase 3 | MACI | Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee | — | recruiting |
| 2030-07 Estimated 50% readout ~2030-09-14 | Phase 3 | autologous cultured chondrocytes on porcine collagen membrane | Chondral Defect, Articular Cartilage Defect | — | recruiting |
Catalyst news & presentations · 3
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- Wednesday, January 14, 2026 at 11:15 a.m. Pacific Timeconferencedata presentationsecondaryVericel presents at 44th Annual J.P. Morgan Healthcare Conference.SEC 8-K
- Wednesday, January 15, 2025 at 7:30 a.m. Pacific Timeconferencedata presentationsecondaryPresentation at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $57 (+29% upside) · 7 analysts
- 2026-07-16Truist SecuritiesBuy
- 2026-05-08HC Wainwright & Co.Buy
- 2026-04-15Truist SecuritiesBuy
- 2026-02-27HC Wainwright & Co.Buy
- 2025-12-18Truist SecuritiesBuy
- 2025-11-10Truist SecuritiesBuy
Competitors — Chondral Defect
- none identified
Recent news
- 2026-07-21Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout Setup - ChartMill
- 2026-07-18Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable Valuation - ChartMill
- 2026-07-17Vericel stock hits 52-week high at 48.41 USD By Investing.com - Investing.com Nigeria
- 2026-07-16VCEL Maintained by Truist Securities -- Price Target Raised to $54.00 - GuruFocus
- 2026-07-16Vericel stock hits 52-week high at 48.41 USD - Investing.com
- 2026-07-16Vericel schedules July 30 webcast for second-quarter update - Stock Titan
- 2026-07-06Vericel stock hits 52-week high at 47.15 USD - Investing.com
- 2026-06-30Vericel (VCEL) CMO exercises options, sells 10,000 shares under 10b5-1 plan - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.